PALB2

PALB2 PALB2 is a human protein that acts as a critical mediator of homologous recombination for DNA repair and genome stability. Identified through studies associating it with BRCA2 and familial breast cancer, PALB2 links multiple DNA repair complexes and chromatin-associated factors to coordinate repair of double-strand breaks. Its role has been delineated in biochemical, genetic, and clinical research involving cancer predisposition, making it a focus of study in translational oncology and molecular genetics.

Function

PALB2 functions as a scaffold that recruits and stabilizes key repair proteins at sites of DNA damage, facilitating homologous recombination in coordination with BRCA1, BRCA2, and the recombinase RAD51. It promotes the assembly of the recombination machinery at stalled replication forks and double-strand breaks, interacting with factors such as PALB2-binding protein partners discovered in proteomic screens from the National Institutes of Health, the European Molecular Biology Laboratory, and academic centers like Harvard University and University of Cambridge. PALB2 also contributes to replication fork protection alongside proteins linked to the Fanconi anemia pathway and is implicated in genome maintenance activities studied at institutes such as the Wellcome Trust and the Howard Hughes Medical Institute.

Structure and Domains

PALB2 contains multiple conserved domains that mediate protein–protein interactions with repair factors characterized in structural biology studies at facilities like the European Synchrotron Radiation Facility and Stanford University. The N-terminal coiled-coil domain mediates interaction with BRCA1, while a central chromatin-association motif and C-terminal WD40-like domain enable binding to BRCA2 and RAD51. Structural features have been resolved using crystallography and cryo-electron microscopy by groups at Max Planck Society and MIT, revealing interfaces targeted by pathogenic variants identified in clinical cohorts collected by consortia including The Cancer Genome Atlas and the International Cancer Genome Consortium.

Clinical Significance and Cancer Risk

Germline loss-of-function variants in PALB2 confer increased risk for hereditary breast cancer identified in case series from institutions such as Mayo Clinic, Dana-Farber Cancer Institute, and Johns Hopkins University. PALB2 mutations are associated with elevated risks for pancreatic cancer reported in studies from Memorial Sloan Kettering Cancer Center and for male and female breast cancer in registries coordinated by National Cancer Institute programs. Biallelic inactivation causes a subtype of Fanconi anemia linked to early-onset malignancy and bone marrow failure described in pediatric cohorts at Great Ormond Street Hospital and St. Jude Children's Research Hospital. Clinical management guidelines published by organizations such as the American Society of Clinical Oncology and the National Comprehensive Cancer Network recommend surveillance and risk-reduction strategies for carriers, and PALB2 status informs therapeutic decisions including the use of PARP inhibitor drugs evaluated in trials run by European Society for Medical Oncology and pharmaceutical partners like AstraZeneca.

Genetic Variants and Inheritance

Pathogenic PALB2 variants follow autosomal dominant inheritance for cancer predisposition with incomplete penetrance documented in family-based studies led by groups at University of Toronto, Karolinska Institutet, and Imperial College London. Population-based variant frequencies have been cataloged in databases assembled by gnomAD and clinical laboratories affiliated with Mayo Clinic Laboratories and Invitae. Recurrent truncating mutations and missense alterations affecting conserved residues in the WD40 domain have been reported in founder studies from Finland, Poland, and Australia, while de novo and compound heterozygous presentations underlie Fanconi anemia phenotypes described by pediatric hematology teams at Children's Hospital of Philadelphia.

Interactions and Pathways

PALB2 occupies a nexus of protein–protein interactions connecting BRCA-mediated homologous recombination, the Fanconi anemia repair network, and replication fork stabilization pathways investigated across collaborative networks including Cold Spring Harbor Laboratory, Sanger Institute, and Broad Institute. It binds directly to BRCA1 and BRCA2, recruits RAD51 and the RAD51 paralogs, and associates with chromatin remodelers and ubiquitin ligases implicated by studies at European Molecular Biology Laboratory and Yale University. PALB2 function is modulated by post-translational modifications catalyzed by kinases studied at Max Planck Institute for Biochemistry and by ubiquitin-dependent signaling characterized by teams at University of California, San Francisco, integrating signals from DNA damage response kinases such as ATM and ATR that were delineated in landmark work from Cold Spring Harbor Laboratory and Rockefeller University.

Category:DNA repair proteins Category:Tumor suppressors Category:Human chromosome 16 genes